Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Endometrial carcinoma

Endometrial carcinoma

Part of Cancer

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Endometrial carcinoma

12 trials tracked for Endometrial carcinoma.

12Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 9 Phase 1 1 Other / NA 2
  1. Phase 2 Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate Completed
  2. Phase 2 Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer Completed
  3. Phase 2 Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma. Completed
  4. Phase 2 Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer Completed
  5. Phase 2 A Study of Nivolumab in Selected Uterine Cancer Patients Completed
  6. Phase 2 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Completed
Show 6 more trials
  1. Phase 2 Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer Completed
  2. Phase 2 Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies Completed
  3. Phase 2 Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies Completed
  4. Phase 1 MK-3475 Immunotherapy in Endometrial Carcinoma Completed
  5. N/A Preoperative Olaparib Endometrial Carcinoma Study (POLEN) Completed
  6. N/A Letrozole as a Treatment of Endometrial Cancer Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Precision oncology enables targeted therapies for gynecologic cancers, though acquired resistance remains a barrier
Oncology Sys. Review
Precision oncology enables targeted therapies for gynecologic cancers, though acquired resistance remains a barrier Precision oncology advances gynecologic cancer care but resistance remains a major barrier
This systematic review examined the current landscape of precision oncology for patients with endometrial, ovarian, and cervical carcinomas.
Molecular reclassification lets doctors use targeted drugs effectively for gynecologic cancers, but tumor evolution creates a major barrier …
Frontiers Apr 9, 2026

Research across Cancer

Related studies from across the Cancer family.

Separate molecular profiling of mixed endometrial carcinoma components yields limited prognostic data in a small retrospective cohort
Oncology Cohort
Separate molecular profiling of mixed endometrial carcinoma components yields limited prognostic data in a small retrospective cohort Separate tumor profiling may reveal hidden risks in mixed endometrial cancer
This hypothesis-generating retrospective cohort analysis included 8 patients with mixed endometrial carcinomas (MEEC).
In mixed endometrial cancer, testing each tumor component separately could uncover risk profiles that standard testing misses.
Frontiers Apr 23, 2026